Short overview on the current standard of treatment in newly diagnosed multiple myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Short overview on the current standard of treatment in newly diagnosed multiple myeloma ; volume:11 ; number:1 ; day:21 ; month:2 ; year:2018 ; pages:59-64 ; date:3.2018
Magazine of European Medical Oncology ; 11, Heft 1 (21.2.2018), 59-64, 3.2018
- Classification
-
Medizin, Gesundheit
- Creator
-
Willenbacher, Ella
- Contributor
-
Balog, Agnes
Willenbacher, Wolfgang
SpringerLink (Online service)
- DOI
-
10.1007/s12254-018-0383-3
- URN
-
urn:nbn:de:101:1-2018052921565674897866
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Willenbacher, Ella
- Balog, Agnes
- Willenbacher, Wolfgang
- SpringerLink (Online service)
Other Objects (12)
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma